接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者持久部分缓解或持久疾病稳定的临床结局与组织学发现
分析IMbrave150研究阿替利珠单抗联合贝伐珠单抗组中持久部分缓解(PR)和持久疾病稳定(SD)患者的结局,并在一组日本和台湾真实世界切除残留肿瘤的患者中分析组织病理学。持久PR患者结局良好,部分可由病理完全缓解(PCR)比例高解释;未发现可靠影像学特征预测PCR。
要点
- IMbrave150中72例PR有56例(77.8%)、144例SD有41例(28.5%)为持久缓解。
- 持久PR中位总生存期不可估计,持久SD为23.7个月。
- 真实世界32例患者38个肿瘤中,PR肿瘤PCR率57.7%高于SD肿瘤16.7%(P = .034)。
核心结论
- 阿替利珠单抗联合贝伐珠单抗组持久PR患者结局良好,部分可由PCR病变比例高解释。
- 早期识别PCR病变可能有助于后续治疗决策。
研究设计与样本
- 分析IMbrave150研究阿替利珠单抗联合贝伐珠单抗组;持久定义为按RECIST v1.1持续超过6个月的PR或SD。
- 组织学分析纳入日本和台湾真实世界中接受阿替利珠单抗联合贝伐珠单抗后切除残留肿瘤的可比患者组。
主要发现
- IMbrave150中72例PR有56例(77.8%)为持久PR,144例SD有41例(28.5%)为持久SD。
- 持久PR患者中位总生存期不可估计,持久SD患者为23.7个月。
- 持久PR患者中位无进展生存期为23.2个月,持久SD患者为13.2个月。
- 真实世界32例患者(23例PR和9例SD)共切除38个肿瘤,PR肿瘤PCR率57.7%高于SD肿瘤16.7%(P = .034)。
- PCR率与从阿替利珠单抗联合贝伐珠单抗开始至切除的时间相关;开始治疗后超过8个月切除的PR肿瘤PCR率为55.6%(5/9)。
临床怎么用
- 作者认为早期识别PCR病变可能有助于后续治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of these patients and the histopathology of the residual tumors. PATIENTS AND METHODS: The IMbrave150 study's atezo-bev group was analyzed. PR or SD per RECIST v1.1 lasting more than 6 months was defined as durable. For histologic analysis, a comparable real-world group of patients from Japan and Taiwan who had undergone resection of residual tumors after atezo-bev was investigated. RESULTS: In the IMbrave150 study, 56 (77.8%) of the 72 PRs and 41 (28.5%) of the 144 SDs were considered durable. The median overall survival was not estimable for patients with durable PR and 23.7 months for those with durable SD. The median progression-free survival was 23.2 months for patients with durable PR and 13.2 months for those with durable SD. In the real-world setting, a total of 38 tumors were resected from 32 patients (23 PRs and nine SDs) receiving atezo-bev. Pathologic complete responses (PCRs) were more frequent in PR tumors than SD tumors (57.7% v 16.7%, P = .034). PCR rate correlated with time from atezo-bev initiation to resection and was 55.6% (5 of 9) for PR tumors resected beyond 8 months after starting atezo-bev, a time practically corresponding to the durable PR definition used for IMbrave150. We found no reliable radiologic features to predict PCR of the residual tumors. CONCLUSION: Durable PR patients from the atezo-bev group showed a favorable outcome, which may be partly explained by the high rate of PCR lesions. Early recognition of PCR lesions may help subsequent treatment decision.
引用
- Shen YC, Liu TH, Nicholas A, et al. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab. J Clin Oncol. 2024. PMID: 39197119. doi:10.1200/JCO.24.00645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。